Department of Conservative Dentistry and Oral Health, Riga Stradins University, Dzirciema str. 20, Riga, 1007, Latvia.
School of Dentistry, College of Biomedical and Life Sciences, Cardiff University, Cardiff, Wales, UK.
Sci Rep. 2024 Apr 7;14(1):8123. doi: 10.1038/s41598-024-58850-w.
Knowledge gaps exist regarding optimal silver diammine fluoride (SDF) regimens and the efficacy of new products for arresting dental caries in young children. We evaluated the effectiveness of 38%-SDF (SDI-RivaStar), Tiefenfluorid (TF) comparing with Placebo (P), all in conjunction with behavioural modification (BM), in preventing major complications (endodontic/extractions/pain)-a patient-centred outcome-due to early childhood caries over 12 months in children under 71-months. A six-arm, patient/parent-blinded, superiority, placebo-controlled randomised control trial at the university clinic in Riga, Latvia, from 1/9/20-31/8/22 (Protocol registration ISRCTN17005348). The trial tested six protocols, using three compounds (P/SDF/TF) under two regimes: annual and biannual (P1/P2/TF1/TF2/SDF1/SDF2) for major complications. Secondary outcomes included minor complications and parental satisfaction. All groups received BM. 373/427 randomised children (87.3%) completed the study. SDF2 had a significantly lower rate and risk of major (21.5%, OR = 0.28, 95%CI [0.11, 0.72], p < 0.05) and minor complications (OR = 0.16 (95%CI [0.05, 0.50], p = 0.002). Overall satisfaction was 96% (p > 0.05). SDF biannual application with BM effectively prevented major complications of early childhood caries and was well accepted by children and their parents. Trial registration number: ISRCTN17005348, principal investigator: Ilze Maldupa, registration date: 30/06/2021.Clinical trial registration number: ISRCTN registry: ISRCTN17005348, https://doi.org/10.1186/ISRCTN17005348 , registration date: 30/06/2021.
关于最佳的银氨氟化(SDF)方案以及新的产品在预防幼儿龋齿方面的功效,目前仍存在知识空白。我们评估了 38%-SDF(SDI-RivaStar)、Tiefenfluorid(TF)与安慰剂(P)联合行为矫正(BM)在预防 71 个月以下幼儿因早期儿童龋齿导致的主要并发症(牙髓/拔牙/疼痛)——以患者为中心的结局——方面的效果,为期 12 个月。这是一项在拉脱维亚里加大学诊所进行的、为期 6 个月、患者/家长双盲、优效性、安慰剂对照的随机对照临床试验,起止日期为 2020 年 9 月 1 日至 2022 年 8 月 31 日(方案注册号 ISRCTN17005348)。该试验测试了六种方案,使用三种化合物(P/SDF/TF),采用两种方案(P1/P2/TF1/TF2/SDF1/SDF2)进行主要并发症检测。次要结局包括次要并发症和家长满意度。所有组均接受 BM。373/427 名随机入组的儿童(87.3%)完成了研究。SDF2 方案的主要(21.5%,OR=0.28,95%CI [0.11, 0.72],p<0.05)和次要并发症(OR=0.16,95%CI [0.05, 0.50],p=0.002)的发生率和风险显著降低。总体满意度为 96%(p>0.05)。BM 联合 SDF 每半年应用可有效预防幼儿龋齿的主要并发症,且儿童及其家长接受度良好。试验注册号:ISRCTN17005348,主要研究者:Ilze Maldupa,登记日期:2021 年 6 月 30 日。临床试验注册号:ISRCTN 注册表:ISRCTN17005348,https://doi.org/10.1186/ISRCTN17005348,登记日期:2021 年 6 月 30 日。